IL1B and deep vein thrombosis: So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab [116] The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) has shown that specific targeting of IL-1β can significantly reduce cardiovascular event rates without lipid or blood pressure lowering [117,118] In addition to cytokines, platelets are also possible targets for anti-inflammatory therapy.